Response to Letter to the Editor From Shaorong Yu and Jifeng Feng
- PMID: 38185512
- DOI: 10.1016/j.jtho.2023.10.018
Response to Letter to the Editor From Shaorong Yu and Jifeng Feng
Comment on
-
Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial".J Thorac Oncol. 2024 Jan;19(1):173-174. doi: 10.1016/j.jtho.2023.08.013. J Thorac Oncol. 2024. PMID: 38185511 No abstract available.
Similar articles
-
Effects of Yu-Ping-Feng polysaccharides on animal growth performance and immune function: a review.Front Vet Sci. 2023 Sep 20;10:1260208. doi: 10.3389/fvets.2023.1260208. eCollection 2023. Front Vet Sci. 2023. PMID: 37799408 Free PMC article. Review.
-
The Ancient Chinese Decoction Yu-Ping-Feng Suppresses Orthotopic Lewis Lung Cancer Tumor Growth Through Increasing M1 Macrophage Polarization and CD4+ T Cell Cytotoxicity.Front Pharmacol. 2019 Nov 8;10:1333. doi: 10.3389/fphar.2019.01333. eCollection 2019. Front Pharmacol. 2019. PMID: 31780946 Free PMC article.
-
Effects of Gan lian Yu ping feng powder on the antibody titers to infectious laryngotracheitis vaccine and some nonspecific immune indexes in chickens.Afr J Tradit Complement Altern Med. 2013 May 16;10(4):70-7. doi: 10.4314/ajtcam.v10i4.12. eCollection 2013. Afr J Tradit Complement Altern Med. 2013. PMID: 24146504 Free PMC article.
-
Answer to the Letter to the Editor of Feng Li et al. entitled "A systematic review with meta-analysis of posterior interbody fusion versus posterolateral fusion in lumbar spondylolisthesis" by Xiaoyang Liu, Yipeng Wang, Guixing Qiu, Xisheng Weng, Bin Yu. Eur Spine J (2013): doi:10.1007/s00586-013-2880-8.Eur Spine J. 2014 Apr;23(4):935-7. doi: 10.1007/s00586-014-3172-7. Epub 2014 Jan 22. Eur Spine J. 2014. PMID: 24448895 Free PMC article. No abstract available.
-
Yu ping feng san for pediatric allergic rhinitis: A systematic review and meta-analysis of randomized controlled trials.Medicine (Baltimore). 2021 Apr 2;100(13):e24534. doi: 10.1097/MD.0000000000024534. Medicine (Baltimore). 2021. PMID: 33787571 Free PMC article.
Cited by
-
Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).Cancers (Basel). 2025 Apr 25;17(9):1443. doi: 10.3390/cancers17091443. Cancers (Basel). 2025. PMID: 40361370 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources